Search

Your search keyword '"Massie, Barry M."' showing total 34 results
Start Over Author "Massie, Barry M." Journal american heart journal
34 results on '"Massie, Barry M."'

1. Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group

Author

Gheorghiade, Mihai, Adams, Kirkwood F., Cleland, John G.F., Cotter, Gad, Felker, G. Michael, Filippatos, Gerasimos S., Fonarow, Gregg C., Greenberg, Barry H., Hernandez, Adrian F., Khan, Sadiya, Komajda, Michel, Konstam, Marvin A., Liu, Peter P., Maggioni, Aldo P., Massie, Barry M., McMurray, John J., Mehra, Mandeep, Metra, Marco, O'Connell, John, O'Connor, Christopher M., Pang, Peter S., Piña, Ileana L., Sabbah, Hani N., Teerlink, John R., Udelson, James E., Yancy, Clyde W., Zannad, Faiez, and Stockbridge, Norman

Published
2009
Full Text
View/download PDF

2. The Antihypertensive and Lipid Lowering reatment to prevent Heart Attack Trial (ALLHAT) heart failure validation study: diagnosis and prognosis

Author

Einhorn, Paula T., Davis, Barry R., Massie, Barry M., Cushman, William C., Piller, Linda B., Simpson, Lara M., Levy, Daniel, Nwachuku, Chuke E., and Black, Henry R.

Subjects
Heart failure -- Diagnosis, Heart failure -- Risk factors, Heart failure -- Patient outcomes, Heart failure -- Research, Antihypertensive drugs -- Research, Cardiac patients -- Prognosis, Health
Published
2007

7. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients

Author

Butler, Jeved, Forman, Daniel E., Abraham, William T., Gottlieb, Stephen S., Loh, Evan, Massie, Barry M., O'Connor, Christopher M., Rich, Michael W., Stevenson, Lynne Warner, Wang, Yonfei, Young, James B., and Krumholz, Harlan M.

Subjects
Diuretics -- Dosage and administration, Kidney failure -- Risk factors, Hospital care -- Complications and side effects, Heart failure -- Complications and side effects, Health
Published
2004

11. A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. Ecadotril Pilot Safety Study

Author

O'Connor, Christopher M., Gattis, Wendy A., Gheorghiade, Mihai, Granger, Christopher B., Gilbert, James, McKenney, James M., Messineo, Frank C., Burnett, John C., Katz, Stuart D., Elkayam, Uri, Kasper, Edward K., Goldstein, Sidney, Cody, Robert J., and Massie, Barry M.

Subjects
Heart failure -- Drug therapy, Enzyme inhibitors -- Health aspects, Health
Published
1999

34. Beta-blocker dosing in community-based treatment of heart failure.

Author

Fowler MB, Lottes SR, Nelson JJ, Lukas MA, Gilbert EM, Greenberg B, Massie BM, Abraham WT, and Franciosa JA

Subjects
Aged, Carvedilol, Community Networks statistics & numerical data, Drug Administration Schedule, Drug Prescriptions statistics & numerical data, Female, Heart Failure classification, Heart Failure mortality, Humans, Length of Stay statistics & numerical data, Male, Middle Aged, Severity of Illness Index, Survival Rate, United States, Adrenergic beta-Antagonists administration & dosage, Carbazoles administration & dosage, Heart Failure drug therapy, Propanolamines administration & dosage
Abstract

Background: Community patients with heart failure (HF) are older, less often treated by HF specialists, and have more comorbidity than those in randomized clinical trials. These differences might affect beta-blocker prescribing in HF., Methods: To explore patterns of beta-blocker prescribing for HF in the community and their association with outcomes, we determined carvedilol doses at end titration in 4113 patients from a community-based beta-blocker HF registry according to physician and patient characteristics, HF severity, and rates of hospitalization and death., Results: Female sex, age > or = 65 years, and left ventricular ejection fraction > or = 35% were associated with lower beta-blocker doses. Average daily dose of beta-blocker was lower with worse baseline New York Heart Association class. More patients of cardiologists achieved carvedilol doses > or = 25 mg twice daily, whereas in those of noncardiologists lower doses were more common. Relative risk of HF hospitalizations or all-cause death was significantly lower with higher doses of beta-blocker., Conclusions: Beta-blocker dosing in community HF appears lower than in randomized clinical trials, especially when prescribed by noncardiologists. At all doses, patients taking the beta-blocker carvedilol have a lower incidence of death and HF hospitalization than those discontinuing it, regardless of physician type in the community setting.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results